Ontario sets December 15 end date for first-line Braftovi–Vectibix funding

Ontario’s Ministry of Health says it will stop issuing new public-funding approvals after December 15, 2026, for first-line treatment with Braftovi (encorafenib) plus Vectibix (panitumumab) in treatment-naïve patients with BRAF V600E-mutated metastatic colorectal cancer. The Executive Officer Notice, dated October 30, sets a specific coverage change for this patient group; it is not a general withdrawal of either medicine or a change to every funded use.

What Ontario’s notice changes

The notice says the combination was initially funded through Ontario’s First Access to Stable and Timely (FAST) pilot while pan-Canadian Pharmaceutical Alliance negotiations were underway. Those negotiations for Braftovi ended without an agreement on July 24, 2026. Ontario has now set December 15 as the end date for new approvals for the described first-line use.

Patients who began publicly funded treatment by December 15 may continue through the manufacturer’s patient support program, according to the notice. That is an important transition detail: the notice does not describe an automatic interruption for people already receiving treatment. It also says other circumstances in which Braftovi or Vectibix are publicly funded are generally unaffected. Pharmacists should therefore avoid treating this as a blanket delisting or assuming that all patients with colorectal cancer are affected.

Why the patient group matters

The restriction is defined by treatment setting and tumour marker. “Treatment-naïve” refers here to patients who have not yet received treatment for metastatic disease, while BRAF V600E identifies a specific tumour mutation. The notice concerns the first-line combination of encorafenib and panitumumab in metastatic colorectal cancer; it does not announce a clinical recommendation about which regimen should replace it.

Practice guidance for pharmacists

• Check the exact indication, BRAF V600E status and treatment line before applying the notice. Do not generalize the change to other colorectal-cancer regimens or other funded uses of either drug.
• For a patient who began publicly funded treatment by December 15, do not tell them that treatment must stop on that date. The notice says ongoing treatment can continue through the manufacturer’s patient support program; confirm the operational arrangements with the oncology team and program.
• If treatment has not started or an approval is pending, ask the prescriber or oncology program to confirm the patient’s coverage status and next steps before promising public reimbursement or continuity after the deadline.
• Do not infer a therapeutic alternative or make a substitution based on this funding notice. Treatment selection remains a clinical decision for the oncology team and patient.
• Use the Ontario notice and current Ontario Drug Benefit program instructions when checking claims. Contact the program help desk identified in the notice if a claim or transition question remains unresolved.

This is a provincial access decision following unsuccessful price negotiations, not a safety alert. Pharmacies serving oncology patients may wish to flag the December date for relevant care teams and verify how patient-support enrollment and claims should be handled as the transition approaches.